Exagen Inc.

NasdaqGM:XGN Lagerbericht

Marktkapitalisierung: US$51.5m

Exagen Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

John Aballi

Geschäftsführender

US$932.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts56.3%
Amtszeit als Geschäftsführer2yrs
Eigentum des Geschäftsführers1.2%
Durchschnittliche Amtszeit des Managements2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.8yrs

Jüngste Management Updates

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Exagen appoints John Aballi as CEO

Oct 17

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Aug 06
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07
Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03
Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05
Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von John Aballi im Vergleich zu den Einnahmen von Exagen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$932kUS$525k

-US$24m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$35m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$1mUS$111k

-US$47m

Vergütung im Vergleich zum Markt: JohnDie Gesamtvergütung ($USD931.95K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: JohnDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

John Aballi (39 yo)

2yrs

Amtszeit

US$931,950

Vergütung

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Tina Nova
Executive Chairman of the Board of Directors5.3yrsUS$132.81k0%
$ 0
John Aballi
CEO, President & Director2yrsUS$931.95k1.17%
$ 602.9k
Kamal Adawi
Corporate Secretary7.1yrsUS$915.09k0.30%
$ 155.8k
Ryan Douglas
Investors Relations Officerno datakeine Datenkeine Daten
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board2yrskeine Datenkeine Daten
Michael Nerenberg
Chief Medical Officer1.4yrskeine Datenkeine Daten

2.0yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: XGNDas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Tina Nova
Executive Chairman of the Board of Directors5.3yrsUS$132.81k0%
$ 0
John Aballi
CEO, President & Director2yrsUS$931.95k1.17%
$ 602.9k
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board4.8yrskeine Datenkeine Daten
Kenneth Bloom
Member of Breast Cancer Advisory Boardno datakeine Datenkeine Daten
Mark Pegram
Member of Breast Cancer Advisory Boardno datakeine Datenkeine Daten
Bruce Robertson
Independent Director5.3yrsUS$33.75kkeine Daten
Thomas Williams
Member of Breast Cancer Advisory Boardno datakeine Datenkeine Daten
Michael Press
Member of Breast Cancer Advisory Boardno datakeine Datenkeine Daten
Lyndsay Harris
Member of Breast Cancer Advisory Boardno datakeine Datenkeine Daten
Raymond Tubbs
Member of Breast Cancer Advisory Boardno datakeine Datenkeine Daten
Arthur Weinstein
Chairman of Scientific Advisory Board4.8yrsUS$130.00kkeine Daten
Frank Stokes
Independent Director3.3yrsUS$82.70k0%
$ 0

4.8yrs

Durchschnittliche Betriebszugehörigkeit

63.5yo

Durchschnittliches Alter

Erfahrener Vorstand: XGNDie Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).